News

The study met its primary endpoint of reducing monthly mean migraine days compared with placebo. The data were presented at the 17th Congress of the International Headache Society

In December last year, the Republic of Lebanon Ministry of Public Health (MOPH) approved Zorvolex as a new chemical entity to treat mild to moderate acute pain in

Chemo Group subsidiary mAbxience is a biopharmaceutical firm specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

Currently, the company is enrolling patients in an open-label multicenter Phase I/II trial, which is designed to evaluate the safety, pharmacokinetics and efficacy of GMI-1271 in combination with

ATL1103 is designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-1 (IGF-1) in the blood and is a potential treatment

Currently, AYX1 is being developed for reduction of acute post-surgical pain and prevention of the transition to persistent or chronic pain with a single administration at the time

SMC has issued its final advice, following a Health Technology Appraisal accepting linagliptin as an additional treatment option for these patients in combination with insulin with or without

The company’s latest report* states that while this growth will be primarily driven by the potential introduction of four late-stage pipeline agents, consisting of reformulations of existing therapies

Both the parties will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators to treat immunological diseases including lupus, Sjögren’s Syndrome, inflammatory bowel disease and